Skip to main content
NRGene Technologies Ltd. logo

NRGene Technologies Ltd. — Investor Relations & Filings

Ticker · NRGN ISIN · IL0011720716 TA Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 24 across all filing types
Latest filing 2023-08-09 Regulatory Filings
Country IL Israel
Listing TA NRGN

About NRGene Technologies Ltd.

https://nrgene.com/

NRGene Technologies Ltd. is a genomics company that develops and commercializes artificial intelligence-based software solutions for the agricultural and food-tech sectors. The company's platform utilizes advanced algorithms to analyze large-scale genomic data, significantly accelerating and optimizing the natural breeding of plants and animals. By decoding genetic information, NRGene enables breeding companies and researchers to identify and select for beneficial traits, such as increased yield, improved quality, and enhanced resilience to environmental stressors. This technology aims to support the development of more productive and sustainable agricultural practices to address global food security challenges.

Recent filings

Filing Released Lang Actions
Following the completion of its contracted two-year engagement under the Tel Aviv Stock Exchange Research Scheme, Frost and Sullivan Independent Equity Research is terminating coverage
Regulatory Filings Classification · 1% confidence The document text is very short (324 characters) and announces the termination of an independent equity research coverage agreement under the Tel Aviv Stock Exchange Research Scheme. This is a specific, non-standard corporate announcement that does not fit clearly into the primary categories like 10-K, ER, or IR. Since it is a specific regulatory/market-related announcement that doesn't match the definitions for DVA, DLST, DIRS, DIV, etc., the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements that do not fit elsewhere.
2023-08-09 Hebrew (modern)
Following the completion of its contracted two-year engagement under the Tel Aviv Stock Exchange Research Scheme, Frost and Sullivan Independent Equity Research is terminating coverage
Regulatory Filings Classification · 1% confidence The document text is highly fragmented and contains non-standard characters, suggesting it might be a raw data extraction or a filing from a non-US jurisdiction (indicated by Hebrew characters and specific date formats like 09/08/2023). Key elements observed are references to 'FROST & SULLIVAN RESEARCH & CONSULTING LTD', a date (09/08/2023), and what appears to be a structured notification format with fields for company identification and dates. Crucially, the document is very short (2666 characters) and seems to be an announcement or notification rather than a comprehensive report like a 10-K or IR. Given the context of regulatory filings and the structure, it strongly resembles a notification of a specific event or filing. Since it doesn't clearly map to AGM, Earnings, Dividend, or Director Dealing, and it's a short notification, the most appropriate general category for miscellaneous regulatory announcements that don't fit elsewhere is 'Regulatory Filings' (RNS). It is not a full report, nor is it clearly a proxy statement (DEF 14A/PSI) or a management discussion (MDA).
2023-08-09 Russian
Analysis update report, target price remains 19.8 NIS
Management Reports Classification · 1% confidence The document is titled "INDEPENDENT EQUITY RESEARCH - NRGENE TECHNOLOGIES LTD - UPDATE REPORT 22.05.2023". It contains detailed analysis of the company's Q1 2023 key events, investment thesis, market analysis (bioinformatics, seed, genotyping), and concludes with a specific stock price target valuation (NIS 29.4 to NIS 32.4). This structure is characteristic of an external research report providing an investment recommendation and detailed analysis, rather than an official regulatory filing (like 10-K, ER, or IR) or a simple announcement (like RPA or RNS). Since there is no specific category for 'Equity Research Report', the closest fit among the provided options that covers detailed analysis and investment outlook, especially when it's an update, is often grouped with Investor Presentations (IP) or sometimes treated as a specialized form of Investor Relations material. However, given the depth of financial and market analysis, and the explicit valuation, it functions most closely to an Investor Presentation or a detailed analysis document. Since 'IP' (Investor Presentation) is defined as a 'Detailed presentation for investors focusing on financials, strategy, and market position,' this document fits that description well, even though it's formatted as research text rather than slides. It is not a regulatory filing, earnings release, or interim report.
2023-05-22 English
Analysis update report, target price remains 19.8 NIS
Earnings Release Classification · 1% confidence The document text contains structured data, dates (e.g., 22/05/2023), references to company identifiers (like 514240779), and a clear reference to a linked file: '��"� ����� �������: *22052023_nrgene_q1_update_report-eng_isa.pdf*'. The presence of 'q1_update_report' strongly suggests a periodic financial report, likely quarterly. The document itself appears to be a cover sheet or an announcement referencing the actual report, rather than the comprehensive report itself (which would be much longer). Since it is a periodic report shorter than a year, the most appropriate classification is Interim / Quarterly Report (IR). However, given the very short length (3881 chars) and the explicit mention of a linked PDF report, it strongly aligns with the 'Report Publication Announcement' (RPA) definition, which covers announcements regarding the release of reports. Since the content is clearly announcing the availability of a quarterly update report, RPA is the most precise fit based on the 'MENU VS MEAL' rule. Q1 2022
2023-05-22 Russian
Analysis update - target price t is updated to NIS 19.8
Investor Presentation Classification · 1% confidence The document is titled 'INDEPENDENT EQUITY RESEARCH - NRGENE TECHNOLOGIES LTD - UPDATE REPORT 13.04.2023'. It contains analysis, key events from Q4 2022, financial analysis referencing the '2022 annual report', updated price targets, and an investment thesis. This structure is characteristic of a third-party research report updating investors on a company's performance and outlook, rather than an official regulatory filing (like 10-K, ER, or IR) issued by the company itself. Since there is no specific category for 'Equity Research Report', and it is a detailed update document, it most closely aligns with an Investor Presentation (IP) or a general update, but given the depth and structure, it functions as a comprehensive update document. However, none of the provided codes perfectly match 'Equity Research'. The document is not a standard regulatory filing, earnings release, or formal company presentation. Given the context of financial reporting databases, this type of third-party analysis often falls under a general 'Information' or 'Presentation' category. Since it provides detailed analysis and outlook, 'Investor Presentation (IP)' is the closest fit among the options for a detailed, forward-looking document, although it is external research. If it were an internal company document detailing strategy and financials, IP would be certain. As external research, it's a grey area, but it's not a regulatory filing (10-K, ER, IR) or a simple announcement (RPA, RNS). I will classify it as Investor Presentation (IP) as it serves a similar informational purpose to an investor audience, despite being external research.
2023-04-13 English
Analysis update - target price t is updated to NIS 19.8
Regulatory Filings Classification · 1% confidence The document is a regulatory filing submitted to the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It follows a standardized reporting format for corporate disclosures, specifically referencing a 'Q4 update report' (as seen in the filename '13042023_nrgene_q4_update_report-eng_isa.pdf'). While it contains metadata about the company and reporting dates, it functions as a formal regulatory notification/filing rather than a full financial report or a standalone earnings release. Given the structure and the context of the filing, it is best classified as a general regulatory filing. Q4 2022
2023-04-13 Russian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.